5671
Shereen Elsayed Mohamed Abdel Aal
Immunohistochemical Study Of Androgen Receptor And Ki67 Expressions In Estrogen Receptor-Negative Invasive Breast Carcinoma
ER, negative, breast carcinoma , AR, Ki67
Background: Estrogen receptor (ER) negative tumors constituted about 30% of breast carcinomas. They lack the expression of ER and no targeted hormone therapies are available for these carcinomas. The androgen receptor (AR) is expressed in a considerable proportion of ER-negative carcinomas, which indicates that AR could be a new target therapy for these tumors. Aim of work: To examine the immunohistochemical expression profiles of AR protein and the proliferation index Ki67 in ER- negative invasive breast carcinoma and to assess the relation between AR expression and Ki67 expression and the relation between the expressions of both androgen receptor and Ki67; and the pathologic prognostic factors. Material &Methods: sixty paraffin blocks of ER-negative breast carcinoma cases were stained immunohistochemically by both AR and Ki67. Positive AR expression was defined as ≥1% nuclear staining. A percentage of 15% or more was considered to be a cutoff point for Ki67 evaluation. Results: AR positivity was detected in 55% of the studied cases. High Ki67 expression was detected in 70% of the studied cases. AR expression was higher in older age, and there were significant positive correlations between the degree of AR expression (AR %, AR intensity and H-score) and age. Ki67 expression was significantly higher in younger age. There was a trend towards a significant negative correlation between Ki67% expression and AR Intensity. Regarding different histological types, tumor grade, tumor size, lymph node status, and immunohistochemical types there was no significant difference between AR positive and AR negative or high Ki67 and low Ki67 cases. Conclusion: We may suggest that AR may havepotential role as target therapy in ER negative breast carcinomas.
2020
M.D
Cairo
Medicine